Temozolomide

The FDA granted fast track designation to enzastaurin for the treatment of patients with newly diagnosed glioblastoma, according to a press release from the agent’s manufacturer.

Olaparib in combination with temozolomide demonstrated promising clinical activity among patients with relapsed small cell lung cancer, according to results of a phase 1/phase 2 trial published in Cancer Discovery.